2024 EMPACT-MI trial: Empagliflozin did not significantly reduce overall heart failure hospitalizations or death after a heart attack, but showed a significant reduction in heart failure hospitalization.

The EMPACT-MI trial at the American College of Cardiology 2024 Annual Scientific Sessions showed that empagliflozin, an SGLT2 inhibitor, did not significantly reduce overall heart failure hospitalizations or death from any cause after a heart attack. However, a secondary analysis indicated a statistically significant reduction in heart failure hospitalization. The primary endpoint was not met, but empagliflozin significantly reduced the risk of certain heart failure outcomes without increasing adverse events.